Thus, ADAM10 activation can ameliorate the downstream cytotoxicity induced by AβO binding to PrPC and represents another potential therapeutic approach to disrupt the AβO-PrPC signaling complex in AD. This evidence concerns the gene ABO and Alzheimer disease.